← Back to Positions
ASP Isotopes
A category-defining platform in the global critical materials and isotope supply chain — powering nuclear medicine, quantum computing, and clean energy.
A category-defining platform in the global critical materials and isotope supply chain — powering nuclear medicine, quantum computing, and clean energy.
ASP Isotopes Inc. (NASDAQ: ASPI) is an advanced materials company transitioning from development into commercial production of high-value isotopes and critical gases. The company employs its proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technology to produce isotopes essential to healthcare, semiconductors, and clean energy.
ASPI has commenced commercial output of Silicon-28, Carbon-14, and Ytterbium-176 at enrichment facilities in Pretoria, South Africa, with first commercial shipments expected across multiple isotopes in 2026. Through partnerships with TerraPower and Fermi America, ASPI is advancing HALEU supply for next-generation nuclear reactors via its subsidiary Quantum Leap Energy. The January 2026 acquisition of Renergen Limited added helium and LNG operations, with Phase 1 nameplate capacity expected Q3 2026. With $333 million in cash and securities and two U.S. radiopharmacy acquisitions completed, ASPI is positioned as a vertically integrated global provider of critical materials.
We hold conviction across multiple dimensions of ASPI's value creation potential.
The only independent Western producer of multiple critical isotopes — reducing dangerous dependency on Russia and China for materials essential to national security, healthcare, and semiconductor manufacturing.
Silicon-28 and Ytterbium-176 shipments have begun — analytically validated by customers. First commercial revenue unlocking $50–70M in near-term potential across quantum computing and nuclear medicine markets.
TerraPower partnership provides long-duration supply visibility in the global HALEU market through 2037. Multiple SMR developers and governments now engaged as the nuclear renaissance accelerates.
Renergen acquisition adds helium — a uniquely constrained commodity with 25–30% of global supply currently offline. Critical for semiconductors, MRI imaging, and quantum cooling infrastructure.
Founder-CEO Paul Mann (ex-Soros, Highbridge, Morgan Stanley) resumed leadership January 2026, calling it a "potentially transformative year." Deep technical bench across isotope enrichment and nuclear fuels.
Four additional laser production plants being procured. JSE secondary listing in preparation. Revenue ramp from development-stage to commercial enterprise underway across all three verticals.
Tracking the milestones that matter for ASPI's value creation trajectory.
January 2026 — Combined company focused on critical isotopes and liquid helium. Phase 1C plant approaching full operation, throughput up ~60%.
March 2026 — Completed all wells required for Phase 1 of the Renergen Helium Project approximately four months ahead of schedule. Helium Phase 1 nameplate capacity targeted Q3 2026.
Wholly-owned subsidiary HQ in Austin, TX. Services contract with Necsa to advance HALEU production. University of Bristol lithium laser enrichment collaboration announced March 2026.
Si-28 and Yb-176 validated by customers. Largest Si-28 order secured with U.S. delivery Q1 2026.
Purchase order for enriched Ba-137 for ion-trap quantum computing — delivery Q1 2026.
CEO warns of fifth supply crisis — 25–30% of global supply offline. Renergen positioned to benefit.
Full-rate commercial Si-28 production for quantum computing
HALEU enrichment milestones through Quantum Leap Energy
Renergen helium nameplate capacity targeted Q3 2026
JSE secondary listing for international investor access
Four additional laser enrichment plants commissioned
Revenue ramp toward $50–70M for 2026–2027; EBITDA target >$300M by 2031